Effects of ruxolitinib on murine regulatory T cells are immune-context dependent
Experimental Hematology · 2023
DOI: 10.1016/j.exphem.2023.07.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Hematology, 2023. Verfasst von Nidhi Aggarwal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, NIH Clinical Center, Bethesda, Maryland. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, CD4-Positive T-Lymphocytes. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, American Association for Dental, Oral, and Craniofacial Research, National Institutes of Health.
Abstract (Originalsprache)
Aplastic anemia is a bone marrow failure (BMF) disorder characterized by pancytopenia and hypocellular marrow from an immune-mediated etiology. Regulatory T cells (Tregs) prevent autoimmunity by suppressing autoreactive T cells. We recently demonstrated the efficacy of ruxolitinib (RUX), a JAK 1/2 inhibitor, in attenuating murine BMF. Herein, we investigated the changes of Tregs in the context of RUX treatment for murine BMF. Tregs are conventionally identified by surface expression of CD4 and CD25, in addition to intracellular transcription factor FoxP3. RUX promoted the expansion of Tregs in BMF mice defined by increased expression of FoxP3 in CD4 T cells but suppressed expression of activation marker CD25 in CD4 and CD8 T cells. In this context, CD25 is no longer a reliable surface marker for Tregs. We observed strong co-expression of FoxP3 with surface marker GITR instead of CD25 in RUX-treated BMF mice. Fluorescence-activated cell sorting (FACS)-sorted CD4+GITRhi cells showed high FoxP3 expression and intact suppressive function in vitro, suggesting GITR to be a surrogate marker for Tregs. In contrast to its expansive effect on Tregs in BMF, RUX suppressed Tregs in normal and sublethal irradiation conditions, indicating that the effects of RUX on Tregs are immune-context dependent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, NIH Clinical Center, Bethesda, Maryland.
- Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, NIH Clinical Center, Bethesda, Maryland. Electronic address: xingmin.feng@nih.gov.
Förderung
- Intramural NIH HHS
- American Association for Dental, Oral, and Craniofacial Research
- National Institutes of Health
- Incyte
- National Heart, Lung, and Blood Institute
- Doris Duke Charitable Foundation
Zitieren
APA
Aggarwal, N., Manley, A. L., Chen, J., Groarke, E. M., Feng, X., & Young, N. S. (2023). Effects of ruxolitinib on murine regulatory T cells are immune-context dependent. Experimental Hematology. https://doi.org/10.1016/j.exphem.2023.07.004
Vancouver
Aggarwal N, Manley AL, Chen J, Groarke EM, Feng X, Young NS. Effects of ruxolitinib on murine regulatory T cells are immune-context dependent. Experimental Hematology. 2023. doi:10.1016/j.exphem.2023.07.004
BibTeX
@article{Aggarwal2023,
author = {Aggarwal, Nidhi and Manley, Ash Lee and Chen, Jichun and Groarke, Emma M and Feng, Xingmin and Young, Neal S},
title = {Effects of ruxolitinib on murine regulatory T cells are immune-context dependent},
journal = {Experimental Hematology},
year = {2023},
doi = {10.1016/j.exphem.2023.07.004}
}
EUVIMED